Did you see us at BHS 2024 to explore the latest insights into EBV+ PTLD with CNS involvement, featuring the groundbreaking work of Professor Daan Dierickx. We are very grateful for his dedication and continuous research, which has significantly advanced our understanding of the pathogenesis of rare aggressive lymphomas and the pursuit of new potential therapeutic targets. Stay tuned to learn, meet, and engage in discussions about urgently needed, effective treatments.
Take a look at the poster: Clinical Experience of Tabelecleucel in Epstein–Barr Virus-Positive Post-transplant Lymphoproliferative Disease (EBV+ PTLD) Involving the Central Nervous System.
NOTE: for the support and as a treatment option within the indication EBV-PTLD the product tabelecleucel EBVALLO® (tabelecleucel) has received a positive opinion by the EMA in October 2022.Assessment report – Ebvallo INN tabelecleucel (europa.eu).
Currently the reimbursement within Belgium and Netherlands is under revision of the local health authorities.
EU-SmPC: Ebvallo, INN-tabelecleucel (europa.eu)
1. Reimbursement status Ebvallo Belgium: under revision
2. Reimbursement status Ebvallo Netherlands: under revision
About the product:
EBVALLO® (tabelecleucel) is a medicine used to treat adults and children from 2 years of age who, after receiving an organ- or a bone marrow-transplantation, develop a blood cancer called Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
It is an orphan approved treatment: Orphan condition Treatment of post-transplant lymphoproliferative disorder
For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.